Terms: = Thyroid cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
61 results:
1. Regulatory and Interacting Partners of PDLIM7 in thyroid cancer.
Rood K; Yamauchi CR; Sharma U; Laxa RT; Robins C; Lanza G; Sánchez-Ruiz K; Khan A; Kim HS; Shields A; Kennedy K; Mirshahidi S; Perez MC; Firek A; Munir I; Simental AA; Khan S
Curr Oncol; 2023 Dec; 30(12):10450-10462. PubMed ID: 38132395
[TBL] [Abstract] [Full Text] [Related]
2. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract] [Full Text] [Related]
3. GSG2 facilitates the progression of human breast cancer through mdm2-mediated ubiquitination of E2F1.
Tang Y; Dai G; Yang Y; Liu H
J Transl Med; 2023 Aug; 21(1):523. PubMed ID: 37537694
[TBL] [Abstract] [Full Text] [Related]
4. Downregulation of mdm2 by small interference RNA induces apoptosis and sensitizes MCF-7 breast cells to resveratrol.
Zhang NX; Ma JF; Li SQ; Yin Z; Li L
Chem Biol Drug Des; 2023 May; 101(5):1082-1088. PubMed ID: 36515454
[TBL] [Abstract] [Full Text] [Related]
5. Rapeseed peptide inhibits HepG2 cell proliferation by regulating the mitochondrial and P53 signaling pathways.
Ma K; Wang Z; Ju X; Huang J; He R
J Sci Food Agric; 2023 Feb; 103(3):1474-1483. PubMed ID: 36168817
[TBL] [Abstract] [Full Text] [Related]
6. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through mdm2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract] [Full Text] [Related]
7. Primary Malignant Peripheral Nerve Sheath Tumor of the Stomach: A Rare Case Report and Review of Literature.
Cui W; Xing L; Fu L; Shi L; Li X
Int J Surg Pathol; 2023 Apr; 31(2):221-226. PubMed ID: 35491655
[TBL] [Abstract] [Full Text] [Related]
8. Combined MEK/mdm2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
Pairawan S; Akcakanat A; Kopetz S; Tapia C; Zheng X; Chen H; Ha MJ; Rizvi Y; Holla V; Wang J; Evans KW; Zhao M; Busaidy N; Fang B; Roth JA; Dumbrava EI; Meric-Bernstam F
Sci Rep; 2022 Jan; 12(1):1248. PubMed ID: 35075200
[TBL] [Abstract] [Full Text] [Related]
9. SARS-CoV-2 detection in primary thyroid sarcoma: coincidence or interaction?
Tanda ML; Ippolito S; Gallo D; Baj A; Novazzi F; Genoni A; Annoni M; Mancini N; Clementi N; Finzi G; Piantanida E; Premoli P; Lai A; Dalla Gasperina D; Maggi F; Uccella S
J Endocrinol Invest; 2022 May; 45(5):1059-1063. PubMed ID: 34984625
[TBL] [Abstract] [Full Text] [Related]
10. p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With thyroid cancer and Autoimmunity.
Arena A; Stigliano A; Belcastro E; Giorda E; Rosado MM; Grossi A; Assenza MR; Moretti F; Fierabracci A
Front Immunol; 2021; 12():728381. PubMed ID: 34539667
[TBL] [Abstract] [Full Text] [Related]
11. LncRNA HCG11/miR-579-3p/mdm2 axis modulates malignant biological properties in pancreatic carcinoma via Notch/Hes1 signaling pathway.
Xu J; Xu W; Yang X; Liu Z; Sun Q
Aging (Albany NY); 2021 Jun; 13(12):16471-16484. PubMed ID: 34230221
[TBL] [Abstract] [Full Text] [Related]
12. Clinical utility of the imunohistochemical co-expression of p53 and mdm2 in thyroid follicular lesions.
Martins MB; de Assis Batista F; Marcello MA; Bufalo NE; Peres KC; Morari EC; Soares FA; Vassallo J; Ward LS
Ann Diagn Pathol; 2021 Aug; 53():151766. PubMed ID: 34111705
[TBL] [Abstract] [Full Text] [Related]
13. Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: A case report.
Zhou P; Zhang Q; Zhu J; Li P
Pathol Res Pract; 2021 Aug; 224():153489. PubMed ID: 34091389
[TBL] [Abstract] [Full Text] [Related]
14. Genetic variants and risk of thyroid cancer among Iranian patients.
Jamshidi M; Farnoosh G; Mohammadi Pour S; Rafiee F; Saeedi Boroujeni A; Mahmoudian-Sani MR
Horm Mol Biol Clin Investig; 2021 Feb; 42(2):223-234. PubMed ID: 33544997
[TBL] [Abstract] [Full Text] [Related]
15. IU1 suppresses proliferation of cervical cancer cells through mdm2 degradation.
Xu L; Wang J; Yuan X; Yang S; Xu X; Li K; He Y; Wei L; Zhang J; Tian Y
Int J Biol Sci; 2020; 16(15):2951-2963. PubMed ID: 33061808
[TBL] [Abstract] [Full Text] [Related]
16. CircTP53 promotes the proliferation of thyroid cancer via targeting miR-1233-3p/mdm2 axis.
Ma W; Zhao P; Zang L; Zhang K; Liao H; Hu Z
J Endocrinol Invest; 2021 Feb; 44(2):353-362. PubMed ID: 32500444
[TBL] [Abstract] [Full Text] [Related]
17. Over expression of CDK4 and mdm2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
Hou TC; Wu PS; Huang WY; Yang YT; Tan KT; Liu SH; Chen YJ; Chen SJ; Su YW
Medicine (Baltimore); 2020 Mar; 99(12):e19577. PubMed ID: 32195970
[TBL] [Abstract] [Full Text] [Related]
18. DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism.
Chen L; Shi Y; Liu N; Wang Z; Yang R; Yan B; Liu X; Lai W; Liu Y; Xiao D; Zhou H; Cheng Y; Cao Y; Liu S; Xia Z; Tao Y
Epigenetics Chromatin; 2019 Oct; 12(1):59. PubMed ID: 31594538
[TBL] [Abstract] [Full Text] [Related]
19. Role of mdm2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
Maruei-Milan R; Heidari Z; Salimi S
J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
[TBL] [Abstract] [Full Text] [Related]
20. Immunohistochemistry in Diagnostic Parathyroid Pathology.
Erickson LA; Mete O
Endocr Pathol; 2018 Jun; 29(2):113-129. PubMed ID: 29626276
[TBL] [Abstract] [Full Text] [Related]
[Next]
